The finding shows that MASM (5 to 20 μM, 48 h) could significantly induce apoptosis of RA-FLS in a dose-dependent manner compared to the control group treated with IL-1β alone (Fig. 3C). This evidence concerns the gene IL1B and rheumatoid arthritis.